Key result
No clinical study data is present in the provided text, which only contains the journal's editorial board and masthead information.
Population
In vitro platelet-poor and platelet-rich models consisting of tissue-factor-induced clots exposed to…
Comparison
Melagatran (20-320 ng/ml) vs Unfractionated heparin (0.1-0.6 U/ml)
Design
Preclinical
Authors
Loading...
Melagatran enhanced fibrinolysis versus heparin in animal platelet-rich clots; leaves open clinical antithrombotic relevance.
Melagatran is more efficient than unfractionated heparin in promoting fibrinolysis, particularly in platelet-rich clots, suggesting a potentially greater antithrombotic activity.
Rossiello et al. (2007) studied this question. No clinical study data is present in the provided text, which only contains the journal's editorial board and masthead information.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: